ea0037ep973 | Thyroid (non-cancer) | ECE2015
Rizza Laura
, Giannetta Elisa
, Sbardella Emilia
, Lauretta Rosa
, Gianfrilli Daniele
, Lenzi Andrea
, Longo Flavia
, Isidori Andrea M
Background: Sunitinib (SUN) is a novel oral multitarget tyrosine-kinase inhibitor (TKI) that has demonstrated its efficacy in the treatment of metastatic renal cell carcinoma (mRCC). The thyroid dysfunction is one of the most common side effects of SUN. The mechanisms inducing thyroid dysfunction are still poorly understood.Aim: Identify the incidence, severity, ultrasonographic changes and pattern of response of thyroid function tests during treatment w...